Participated · Equity · Jun 2025

myLaurel has built a technology-enabled, hospital-aligned model for acute and transitional care at home, combining AI-driven logistics orchestration with virtual physician oversight and hands-on clinical teams. Operating in markets such as New York City and New Orleans, the company partners with health systems including Ochsner Health, LCMC Health, and Maimonides Medical Center to alleviate emergency-department crowding and workforce shortages. Its platform reports a 49 percent reduction in readmissions, a 6-to-1 return on investment for hospital partners, and patient satisfaction scores above 90 NPS, illustrating strong clinical and financial outcomes. The new capital will fund a nationwide rollout, expanding partnerships with major U.S. health systems and scaling its AI infrastructure. Led by CEO Juan Vallarino and President & Chief Medical Officer Dr. Marcy Carty, the team brings deep experience in value-based and technology-enabled care models. Future plans center on rapid geographic expansion while maintaining high standards of clinical quality and patient experience. No revenue or user counts were disclosed in the articles.

Participated · Series A · Sep 2023

DeLorean Artificial Intelligence is a Miami, FL–based AI technology development company led by CEO and founder Dr. MacLaughlin. The company builds sentient and semi-sentient systems of intelligence designed to address business and economic challenges for Fortune 500 companies. Its core product, Medical AI, creates mathematical profiles of patient journeys and treatment methodologies to provide a predictive and proactive approach to treatment. Beyond Medical AI, DeLorean holds patent-pending rights to several proprietary AI capabilities including CPG Sales AI, a Ticket Analysis Prediction Engine (TAPE AI), and CRM AI. CRM AI, described as the company’s first patented product, can predict deal winnability and estimate financial impacts on revenue and costs, and works with any CRM platform while analyzing structured and unstructured data. The company says it will use new funds to accelerate adoption of Medical AI across the U.S., Europe, the Middle East, and Latin & South America; to date it has raised approximately $11M.